RiteMED Telmisartan Adverse Reactions

Concise Prescribing Info Full Prescribing Info Contents Description Action Indications/Uses Dosage/Direction for Use Overdosage Contraindications Special Precautions Use In Pregnancy & Lactation Adverse Reactions Side Effects Drug Interactions Storage MIMS Class ATC Classification Regulatory Classification Presentation/Packing

Full Prescribing Info

Adverse Reactions

The overall incidence of adverse events reported with Telmisartan (41.4%) was usually comparable to placebo (43.9%) in controlled clinical trials in patients treated for hypertension. The incidence of adverse events was not dose related and showed no correlation with gender, age or race of the patients.
The safety profile of Telmisartan in patients treated for reduction of cardiovascular morbidity was consistent with that obtained in hypertensive patients. The adverse drug reactions listed as follows have been accumulated from controlled clinical trials in patients treated for hypertension and from post-marketing reports. The listing also takes into account serious adverse events and adverse events leading to discontinuation reported in three clinical long-term studies including 21642 patients treated with Telmisartan for reduction of cardiovascular morbidity for up to six years.

View ADR Reporting Link

RiteMED Telmisartan Adverse Reactions

telmisartan

Manufacturer:

Intas

Distributor:

RiteMED